The three most expensive drug categories, on a per-member/per-year basis for the PBM's clients, increased by 19% or more in 2016, and similar growth is expected in the next three years. Per-patient spending on HCV drugs, however, declined by 34% last year.
The three most expensive drug therapy classes in the US market in 2016 – inflammatory conditions, diabetes and oncology – increased in expense for health plans on a per-member/per-year (PMPY) basis by at least 19%, a trend that is expected to continue during the next three years, Express Scripts Holding Co. noted in its 2016 Drug Trend Report, released Feb. 6.
The other therapeutic area in Express Scripts's top 15 with double-digit growth was HIV, the sixth-most expensive, up 21.7% compared...
Head of hematology clinical development Andres Sirulnik talked to Scrip about the positive Phase III results for the siRNA medicine.
The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.
Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.
